MedTrace Logo

Long-term Outcomes After Conversion to Belatacept

NCT04733131 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 324

Last updated 2021-02-01

No results posted yet for this study

Summary

belatacept is a selective T-cell co-stimulation blocker that was approved by Food and Drug Administration (FDA) in 2011 for the prophylaxis of graft rejection in adult kidney transplant recipients. This treatment is indicated as an alternative to Calcineurin Inhibitors (CNIs) for prophylaxis of graft rejection in de novo renal transplant recipients. Long term efficacy and safety outcomes of a kidney transplant population converted to a belatacept regimen after transplant have not been yet reported.

Conditions

  • Kidney Transplant Failure and Rejection
  • Immunosuppression
  • Graft Loss
  • Drug Effect Prolonged

Interventions

DRUG

Conversion to a belatacept regimen

belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.

Sponsors & Collaborators

  • Paris Translational Research Center for Organ Transplantation

    lead OTHER

Principal Investigators

  • Alexandre Loupy, MD, PhD · Paris Translational Research Center for Organ Transplantation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-01
Primary Completion
2021-06-30
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733131 on ClinicalTrials.gov